Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Peanut allergy breakthrough? new drug combo aims to build lasting tolerance

NCT ID NCT07015996

First seen Nov 01, 2025 · Last updated May 23, 2026 · Updated 37 times

Summary

This study tests whether adding the drug tezepelumab to peanut oral immunotherapy (OIT) helps people with peanut allergy safely eat more peanut without symptoms. About 62 people aged 12 to 55 with severe peanut allergy will receive either tezepelumab or a placebo along with OIT for 56 weeks, then stop all treatment for 12 weeks. The goal is to see if they can eat a large amount of peanut (4000 mg protein) without an allergic reaction after stopping therapy.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PEANUT ALLERGY are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Arkansas Children's Hospital Research Institute: Department of Pediatrics, Allergy & Immunology

    Little Rock, Arkansas, 72202, United States

  • Boston Children's Hospital: Allergy and Asthma Program

    Boston, Massachusetts, 02115, United States

  • Cincinnati Children's Hospital Medical Center: Division of Allergy and Immunology

    Cincinnati, Ohio, 45229, United States

  • Icahn School of Medicine at Mount Sinai: Department of Pediatrics Allergy & Immunology

    New York, New York, 10029-6574, United States

  • Johns Hopkins Children's Center: Department of Allergy & Immunology

    Baltimore, Maryland, 21287, United States

  • Massachusetts General Hospital: Department of Medicine: Allergy & Clinical Immunology Unit

    Boston, Massachusetts, 02114, United States

  • North Carolina Children's Hospital: Department of Pediatrics, Division of Allergy, Immunology and Rheumatology

    Chapel Hill, North Carolina, 27599, United States

  • The University of Michigan: Division of Allergy and Clinical Immunology

    Ann Arbor, Michigan, 48105, United States

  • University of California, Los Angeles: Department of Medicine, Division of Clinical Immunology and Allergy

    Los Angeles, California, 90095, United States

  • University of Texas Southwestern Medical Center: Division of Allergy and Immunology

    Dallas, Texas, 75390-9063, United States

Conditions

Explore the condition pages connected to this study.